Tvardi is conducting Phase 2 clinical trials with TTI-101, an oral drug that inhibits STAT3, a protein that plays a key role in cancer and fibrosis.

In cancer, STAT3 can lead to tumor growth and metastasis, as well as limit the body’s ability to mount an immune response against cancer cells.

In fibrotic conditions, such as Idiopathic Pulmonary Fibrosis (IPF), STAT3 plays a key role in fibrosis (scarring of lung tissues) and limits the body’s ability to repair damaged cells.

Human studies have shown that TTI-101 has the potential to benefit patients with conditions where STAT3 plays a central role, including cancer and IPF.  TTI-101 is a pill taken by mouth twice daily.